PMID- 19530505
OWN - NLM
STAT- MEDLINE
DCOM- 20090728
LR  - 20181201
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 13 Suppl 1
DP  - 2009 Mar
TI  - Immunologic and genetic links between spondylarthropathies and inflammatory bowel 
      diseases.
PG  - 1-9
AB  - BACKGROUND AND OBJECTIVE: Spondyloarthritis (SpA) is a well recognized 
      extraintestinal manifestation of Inflammatory Bowel Diseases (IBDs), either 
      Crohn's Disease(CD) or Ulcerative Colitis (UC). A much larger percentage of SpA 
      patients have subclinical gut inflammation manifested either by endoscopic 
      findings or by histology. The aim of the present article is to review clinical 
      and experimental evidences regarding the immunological and genetic links between 
      gut and joint inflammation in IBDs and SpA. EVIDENCE AND INFORMATION SOURCES: A 
      systematic review using PubMed database entering IBD and SpA as key words was 
      performed. STATE OF THE ART: The association with HLA-B27 is less strong in 
      IBD-associated SpA than in Idiopathic Ankylosing Spondylitis (AS) and there is 
      some evidence for an association between gut inflammation in SpA and CD related 
      CARD15 mutations. A common inflammatory pathogenic pathway has been suggested in 
      gut and joint inflammation in IBD. Treatment of SpA associated with IBD has 
      gained major advances in recent years with the advent of anti-TNF-alpha therapy. 
      PERSPECTIVES: The adaptive immune response in IBD is thought to be strictly 
      differentiated between Th1 and Th2 in CD and UC respectively. Recent findings, 
      however, suggest that novel effector pathways could drive tissue damage. The most 
      important pathway now emerging is the IL-23/IL-17 axis. CONCLUSIONS: Present and 
      future advancements of knowledge on mechanisms of inflammation will likely lead 
      to new therapeutic targets.
FAU - Faustini, F
AU  - Faustini F
AD  - Department of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy.
FAU - Zoli, A
AU  - Zoli A
FAU - Ferraccioli, G F
AU  - Ferraccioli GF
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (Nod2 Signaling Adaptor Protein)
SB  - IM
MH  - Genetic Predisposition to Disease
MH  - HLA-B27 Antigen/metabolism
MH  - Humans
MH  - Immunity, Innate
MH  - Immunity, Mucosal
MH  - Inflammatory Bowel Diseases/complications/*genetics/*immunology
MH  - Models, Biological
MH  - Nod2 Signaling Adaptor Protein/genetics
MH  - Polymorphism, Single Nucleotide
MH  - Spondylarthropathies/complications/*genetics/*immunology
RF  - 56
EDAT- 2009/06/18 09:00
MHDA- 2009/07/29 09:00
CRDT- 2009/06/18 09:00
PHST- 2009/06/18 09:00 [entrez]
PHST- 2009/06/18 09:00 [pubmed]
PHST- 2009/07/29 09:00 [medline]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2009 Mar;13 Suppl 1:1-9.